Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab (APHARIPE)

13. November 2026 aktualisiert von: University Hospital, Caen

Perceived Autonomy of Patients (or Family Caregivers) With Severe or Moderate Hemophilia A for Performing Intravenous Injections Under Emicizumab Prophylaxis

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if <1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.

Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.

The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

Hemophilia is a rare constitutional bleeding disorder. Severe hemophilia A corresponds to a severe factor VIII (FVIII) deficiency (<1%), and moderate hemophilia A to an FVIII level between 1% and 5%. Both forms manifest as spontaneous or post-traumatic/surgical intra-articular bleeds (hemarthroses) or muscle hematomas, which can jeopardize functional prognosis if recurrent.

Until April 2018, the treatment of severe and moderate hemophilia A was exclusively substitutive, relying on intravenous (IV) injections of clotting factor concentrates (FVIII, or bypassing agents such as rFVIIa or aPCC for patients with anti-FVIII inhibitors). Used both prophylactically (2 to 3 IV infusions per week) and on-demand for acute bleeds, this regimen enabled most patients-or family caregivers for younger children-to acquire and maintain autonomy in performing IV injections through frequent practice.

Since April 2018 for patients with inhibitors, March 2020 for severe hemophilia A without inhibitors, and January 2023 for moderate hemophilia A, subcutaneous prophylaxis with the monoclonal antibody emicizumab (Hemlibra®) has been available. While emicizumab converts the bleeding phenotype to that of mild hemophilia, it is strictly prophylactic; IV clotting factor infusions remain required in the event of breakthrough bleeding. Because bleeding events become very rare under emicizumab, the frequency of IV injections drops sharply.

The investigators hypothesize that patients (or family caregivers) who were previously autonomous in performing IV clotting factor infusions progressively lose technical competence and/or self-efficacy during emicizumab prophylaxis. APHARIPE is a multicenter, exploratory, non-interventional questionnaire-based study designed to evaluate patients' and caregivers' perceived loss of autonomy. Healthcare providers caring for this population will also be surveyed to assess potential perception gaps regarding the impact of this loss of autonomy on overall patient management.

The study aims to include 450 patients (or family caregivers) with severe or moderate hemophilia A treated with emicizumab who were previously autonomous for IV injections, over an 18-month recruitment period. Findings will help identify specific difficulties, question the relevance of ongoing IV injection training, assess the impact on acute bleed management and the need to keep emergency treatments at home, and ultimately optimize patient care pathways and therapeutic education practices

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

450

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Nicolas GUERIN, Registered Nurse
  • Telefonnummer: + 33 2 31 06 52 10
  • E-Mail: guerin-n@chu-caen.fr

Studienorte

      • Angers, Frankreich, 49933
        • Centre Hospitalier Universitaire d'Angers
        • Kontakt:
      • Bordeaux, Frankreich, 33076
        • Centre Hospitalier Universitaire de Bordeaux - Hôpital Pellegrin
        • Kontakt:
      • Bron, Frankreich, 69677
        • Hospices Civiles de Lyon - Hôpital Louis Pradel
        • Kontakt:
      • Caen, Frankreich, 14000
        • Centre Hospitalier Universitaire de Caen
        • Kontakt:
      • Chambéry, Frankreich, 73011
      • Clermont-Ferrand, Frankreich, 63000
        • Centre Hospitalier Universitaire de Clermont Ferrand
        • Kontakt:
      • Dijon, Frankreich, 21079
        • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand
        • Kontakt:
      • Grenoble, Frankreich
        • Centre Hospitalier Universitaire de Grenoble
        • Kontakt:
      • Le Kremlin-Bicêtre, Frankreich, 94275
        • AP-HP - Hôpital Bicêtre
        • Kontakt:
      • Le Mans, Frankreich
        • Centre Hospitalier du Mans
        • Kontakt:
      • Lille, Frankreich, 59037
        • Centre Hospitalier Régional Universitaire principal de la métropole lilloise
        • Kontakt:
      • Marseille, Frankreich, 13385
        • AP-HM - Hôpitaux Universitaires de Marseille Timone
        • Kontakt:
      • Montpellier, Frankreich, 34295
        • Centre Hospitalier Universitaire de Montpellier
        • Kontakt:
      • Nantes, Frankreich, 44093
        • Centre Hospitalier Universitaire Hôtel-Dieu
        • Kontakt:
      • Paris, Frankreich, 75679
        • AP-HP - Hôpital Cochin
        • Kontakt:
      • Poitiers, Frankreich, 86021
        • Centre Hospitalier Universitaire de Poitiers - Hôpital Jean Bernard
        • Kontakt:
      • Pringy, Frankreich, 74374
        • Centre Hospitalier Annecy Gennevois
        • Kontakt:
      • Rennes, Frankreich
        • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
        • Kontakt:
      • Saint-Denis, Frankreich, 97400
      • Saint-Etienne, Frankreich, 45055
        • Centre Hospitalier Universitaire de Saint Etienne - Hôpital Nord
        • Kontakt:
      • Strasbourg, Frankreich, 67200
        • Centre Hospitalier Universitaire de Strasbourg - Hôpital de Hautepierre
        • Kontakt:
      • Toulouse, Frankreich, 31059
      • Tours, Frankreich, 37044
        • Centre Hospitalier Régional Universitaire de Tours - Hôpital Trousseau
        • Kontakt:
      • Vandœuvre-lès-Nancy, Frankreich, 54500
        • Centre Hospitalier Régional Universitaire de Nancy - Hôpital Brabois
        • Kontakt:
      • Pointe-à-Pitre, Guadeloupe, 97110
        • Centre Hospitalier Universitaire de Pointe à Pitre - Hôpital Ricou
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population consists of adult and minor patients with severe (FVIII <1%) or moderate (FVIII 1%-5%) hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year-or parent caregivers (excluding healthcare professionals) for non-autonomous minor patients-who were previously autonomous in performing intravenous clotting factor injections prior to emicizumab initiation. Healthcare professionals (physicians and nurses) involved in the care of these patients will also be enrolled. Participants will be recruited during routine clinical follow-up visits across participating French hemophilia treatment centers

Beschreibung

Inclusion Criteria:

For autonomous adult patients (patient enrolled in the study):

  • Adult patient (>= 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained

For autonomous pediatric/minor patients (patient enrolled in the study):

  • Minor patient (< 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained
  • Non-opposition obtained from parents or legal guardians

For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):

  • Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
  • Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Parent caregiver non-opposition obtained

For healthcare providers:

  • Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
  • Healthcare provider non-opposition obtained

Exclusion Criteria:

For autonomous adult patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For autonomous pediatric/minor patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For non-autonomous pediatric/minor patients:

- Parent caregiver who is a healthcare professional

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: OTHER
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Patients or Family Caregivers

Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy

Healthcare Providers

Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of Patients or Family Caregivers Reporting a Perceived Loss of Autonomy for Performing Intravenous Clotting Factor Injections
Zeitfenster: At baseline (single questionnaire completion)

Assessed using Question 9 of the study-specific patient/caregiver questionnaire (4-point Likert scale: "not at all autonomous", "slightly autonomous", "moderately autonomous", "completely autonomous"). Responses of "not at all autonomous", "slightly autonomous", or "moderately autonomous" will be classified as a perceived loss of autonomy. Expressed as absolute frequency and percentage of respondents

At baseline (single questionnaire completion)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Frequency of Clotting Factor Concentrate Use Under Emicizumab Prophylaxis
Zeitfenster: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients requiring intravenous clotting factor concentrates (FVIII or bypassing agents) while receiving emicizumab prophylaxis, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Keeping Clotting Factor Concentrates at Home
Zeitfenster: At baseline (single questionnaire completion)

Percentage of patients who report having clotting factor concentrates (FVIII or bypassing agents) stored at home, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting Anticipated Difficulties With Performing a Future Intravenous Injection
Zeitfenster: At baseline (single questionnaire completion)

Percentage of patients or family caregivers who report experiencing or anticipating difficulties in performing a subsequent intravenous clotting factor injection, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Types of Difficulties Encountered During Intravenous Clotting Factor Injections
Zeitfenster: At baseline (single questionnaire completion)

Categorization and percentage distribution of specific technical or psychological difficulties reported by patients or family caregivers when performing intravenous injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Home Nursing Assistance
Zeitfenster: At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for a community nurse (IDE) to perform repeated intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients Expressing a Need for a Therapeutic Patient Education Program
Zeitfenster: At baseline (single questionnaire completion)

Percentage of patients reporting the need for therapeutic education sessions to maintain their autonomy in performing intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Expressing a Need for Initial Intravenous Injection Training
Zeitfenster: At baseline (single questionnaire completion)

Percentage of patients or family caregivers reporting the need for initial training to learn how to perform intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Frequency and Quantity of Unused Expired Clotting Factor Concentrates at Home
Zeitfenster: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients having unused expired FVIII concentrates or bypassing agents at home, along with the total number of expired doses reported via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Patients or Caregivers Reporting an Impact of Perceived Loss of Autonomy on Bleeding Event Management
Zeitfenster: At baseline (single questionnaire completion)

Absolute and relative frequency (percentage) of patients or family caregivers reporting that their perceived loss of autonomy negatively affected the management of an acute bleeding episode, assessed via the patient/caregiver questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Patient or Caregiver Autonomy for Intravenous Injections
Zeitfenster: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to maintain patients' or family caregivers' autonomy for intravenous administration of clotting factor concentrates, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Supporting the Maintenance of Clotting Factor Concentrates at Home
Zeitfenster: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider it necessary to keep emergency clotting factor concentrates at patients' homes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)
Proportion of Healthcare Providers Perceiving a Delay in Bleeding Management Due to Reduced Patient Autonomy
Zeitfenster: At baseline (single questionnaire completion)

Percentage of healthcare professionals who consider that a decreased sense of autonomy for performing intravenous injections delays the management of acute bleeding episodes, assessed via the healthcare provider questionnaire

At baseline (single questionnaire completion)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Nicolas GUERIN, Registered Nurse, Centre Hospitalier Universitaire de Caen - Centre de Ressources et de Compétences Maladies Hémorragiques Rares

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Januar 2027

Primärer Abschluss (Geschätzt)

30. Juni 2028

Studienabschluss (Geschätzt)

30. Juni 2028

Studienanmeldedaten

Zuerst eingereicht

13. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren